

Wyost[®] (denosumab-bbdz) – First-time interchangeable biosimilar launch

- On June 2, 2025, Sandoz launched [Wyost \(denosumab-bbdz\)](#), biosimilar and *interchangeable* to Amgen's [Xgeva[®] \(denosumab\)](#).

Wyost is available at a list price (Wholesale Acquisition Cost [WAC]) 7% below the current Xgeva list price (\$3208.26 per package).

- Wyost was [FDA-approved](#) in March 2024.
- Additional biosimilars to Xgeva have been approved with pending launch dates:
 - Samsung Bioepis' Xbryk[™] (denosumab-dssb)
 - Celltrion's Osenvelt[®] (denosumab-bmwo)
 - Fresenius Kabi's Bomynta[®] (denosumab-bnht).
- Wyost and Xgeva share the following indications:
 - Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors
 - Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
 - Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy